FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913294305> ?p ?o ?g. }

• W2913294305 endingPage "293" @default.
• W2913294305 startingPage "287" @default.
• W2913294305 abstract "Patients with chronic kidney disease (CKD) have higher risk of developing cardiovascular disease. In CKD patients the mechanisms involved in, endothelial damage and the role of different drugs used on these patients are not completely understood. The aim of this work is to analyze the effect of statins and platelet antiaggregant (PA) on endothelial microvesicles (EMVs) and other markers of endothelial dysfunction. Cross-sectional study of 41 patients with CKD 3b-4 and 8 healthy volunteers. Circulating levels of EMVs, vascular endothelial growth factor (VEGF), and advance oxidized protein products (AOPPS) were quantified and the correlation with different comorbidity variables and therapeutic strategies were evaluated. EMVs are increased in CKD patients as compared with controls (171.1 vs. 68.3/μl, p < 0.001). It was observed a negative correlation between age and EMVs. Statins and PA were associated with a reduction in EMVs and VEGF levels, independently of the serum total cholesterol levels (TC). The levels of AOPPS and VEGF were not different in CKD vs. controls. CKD is associated with a change in EMVs, VEGF and AOPP levels. The treatment with statins and PA normalizes these values to almost the observed in controls and this effect is independently of the prevailing TC level. These findings explain the existence of the pleiotropic effects of statins and PA which deserve further studies. Los pacientes con insuficiencia renal crónica (IRC) corren mayor riesgo de desarrollar enfermedad cardiovascular. En los pacientes con IRC, los mecanismos implicados en la disfunción endotelial y el papel de los diferentes fármacos utilizados en estos pacientes no se conocen por completo. El objetivo de este artículo es analizar el efecto de las estatinas y los antiagregantes plaquetarios (AP) sobre las microvesículas endoteliales (MVE) y otros marcadores de la disfunción endotelial. Estudio transversal con 41 pacientes con IRC 3b-4 y 8 voluntarios sanos. Se cuantificaron los niveles de MVE, factor de crecimiento vascular endotelial (FCVE) y productos avanzados de oxidación de proteínas (AOPP, por sus siglas en inglés) en la circulación y se evaluó la correlación con diferentes variables de comorbilidad y estrategias terapéuticas. Las MVE aumentaron en pacientes con IRC al comparar los niveles con los controles (171,1 frente a 68,3/μl; p < 0,001). Se observó una correlación negativa entre la edad y las MVE. Las estatinas y los AP se asociaron con una reducción de los niveles de MVE y FCVE, independientemente de los niveles séricos de colesterol total (CT). Los niveles de AOPP y FCVE no fueron diferentes entre los pacientes con IRC y los controles. La IRC se asocia con un cambio de los niveles de MVE, FCVE y AOPP. El tratamiento con estatinas y AP normaliza estos valores a casi los observados en los controles y este efecto es independiente del nivel de CT predominante. Estos hallazgos explican la existencia de los efectos pleiotrópicos de las estatinas y los AP que merecen estudios adicionales." @default.
• W2913294305 created "2019-02-21" @default.
• W2913294305 creator A5001999066 @default.
• W2913294305 creator A5002874862 @default.
• W2913294305 creator A5017929425 @default.
• W2913294305 creator A5019936644 @default.
• W2913294305 creator A5021651261 @default.
• W2913294305 creator A5036646028 @default.
• W2913294305 creator A5039134021 @default.
• W2913294305 creator A5040199618 @default.
• W2913294305 creator A5060013615 @default.
• W2913294305 date "2019-05-01" @default.
• W2913294305 modified "2023-09-29" @default.
• W2913294305 title "Statins and antiplatelet agents are associated with changes in the circulatory markers of endothelial dysfunction in chronic kidney disease" @default.
• W2913294305 cites W1495627117 @default.
• W2913294305 cites W1964564177 @default.
• W2913294305 cites W1980366114 @default.
• W2913294305 cites W1998343049 @default.
• W2913294305 cites W2026880762 @default.
• W2913294305 cites W2028466973 @default.
• W2913294305 cites W2035655266 @default.
• W2913294305 cites W2044451058 @default.
• W2913294305 cites W2071281057 @default.
• W2913294305 cites W2091630980 @default.
• W2913294305 cites W2092107845 @default.
• W2913294305 cites W2102080772 @default.
• W2913294305 cites W2116643762 @default.
• W2913294305 cites W2120309176 @default.
• W2913294305 cites W2129591434 @default.
• W2913294305 cites W2134120087 @default.
• W2913294305 cites W2137742067 @default.
• W2913294305 cites W2139291989 @default.
• W2913294305 cites W2145433321 @default.
• W2913294305 cites W2153982586 @default.
• W2913294305 cites W2235966547 @default.
• W2913294305 cites W2260621312 @default.
• W2913294305 cites W2333672259 @default.
• W2913294305 cites W2608697804 @default.
• W2913294305 doi "https://doi.org/10.1016/j.nefroe.2019.01.002" @default.
• W2913294305 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30732927" @default.
• W2913294305 hasPublicationYear "2019" @default.
• W2913294305 type Work @default.
• W2913294305 sameAs 2913294305 @default.
• W2913294305 citedByCount "3" @default.
• W2913294305 countsByYear W29132943052021 @default.
• W2913294305 crossrefType "journal-article" @default.
• W2913294305 hasAuthorship W2913294305A5001999066 @default.
• W2913294305 hasAuthorship W2913294305A5002874862 @default.
• W2913294305 hasAuthorship W2913294305A5017929425 @default.
• W2913294305 hasAuthorship W2913294305A5019936644 @default.
• W2913294305 hasAuthorship W2913294305A5021651261 @default.
• W2913294305 hasAuthorship W2913294305A5036646028 @default.
• W2913294305 hasAuthorship W2913294305A5039134021 @default.
• W2913294305 hasAuthorship W2913294305A5040199618 @default.
• W2913294305 hasAuthorship W2913294305A5060013615 @default.
• W2913294305 hasBestOaLocation W29132943051 @default.
• W2913294305 hasConcept C126322002 @default.
• W2913294305 hasConcept C134018914 @default.
• W2913294305 hasConcept C2778163477 @default.
• W2913294305 hasConcept C2778653478 @default.
• W2913294305 hasConcept C2779134260 @default.
• W2913294305 hasConcept C2780972559 @default.
• W2913294305 hasConcept C71924100 @default.
• W2913294305 hasConcept C90924648 @default.
• W2913294305 hasConceptScore W2913294305C126322002 @default.
• W2913294305 hasConceptScore W2913294305C134018914 @default.
• W2913294305 hasConceptScore W2913294305C2778163477 @default.
• W2913294305 hasConceptScore W2913294305C2778653478 @default.
• W2913294305 hasConceptScore W2913294305C2779134260 @default.
• W2913294305 hasConceptScore W2913294305C2780972559 @default.
• W2913294305 hasConceptScore W2913294305C71924100 @default.
• W2913294305 hasConceptScore W2913294305C90924648 @default.
• W2913294305 hasFunder F4320334923 @default.
• W2913294305 hasIssue "3" @default.
• W2913294305 hasLocation W29132943051 @default.
• W2913294305 hasOpenAccess W2913294305 @default.
• W2913294305 hasPrimaryLocation W29132943051 @default.
• W2913294305 hasRelatedWork W1966834268 @default.
• W2913294305 hasRelatedWork W1972175381 @default.
• W2913294305 hasRelatedWork W2005998106 @default.
• W2913294305 hasRelatedWork W2019813684 @default.
• W2913294305 hasRelatedWork W2032958076 @default.
• W2913294305 hasRelatedWork W2035331946 @default.
• W2913294305 hasRelatedWork W2075372262 @default.
• W2913294305 hasRelatedWork W2166236611 @default.
• W2913294305 hasRelatedWork W2168843442 @default.
• W2913294305 hasRelatedWork W4242761889 @default.
• W2913294305 hasVolume "39" @default.
• W2913294305 isParatext "false" @default.
• W2913294305 isRetracted "false" @default.
• W2913294305 magId "2913294305" @default.
• W2913294305 workType "article" @default.